Everest Group Ltd (EG) Stock News

Rosen Law Firm has filed class action lawsuits against Everest Group, Ltd., FuelCell Energy, Inc., and DICK'S Sporting Goods, Inc. on behalf of investors who purchased securities during specified periods. The firm is seeking lead plaintiffs and encouraging investors to join the litigation. The Everest Group lawsuit alleges materially false statements regarding casualty risk exposure, inadequate pricing, and insufficient reserves.

Rosen Law Firm announces securities class action lawsuits against DICK'S Sporting Goods, Everest Group, and FuelCell Energy. The DKS lawsuit alleges the company made materially false statements about its Foot Locker acquisition cleanup efforts and failed to disclose exposure to excess inventory and promotional pressures in the athletic footwear industry, resulting in inability to achieve promised sales growth and profits. Investors who purchased shares during specified class periods are encouraged to join the litigation before respective deadlines.

London Stock Exchange Group plc's unsponsored ADR (LSEGY) has been upgraded to a Zacks Rank #2 (Buy) rating, reflecting upward trends in earnings estimates. The company is expected to earn $1.62 per share for fiscal year 2026 with no year-over-year change, though analysts have raised consensus estimates by 2.5% over the past three months. The upgrade positions LSEGY in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation.

Everest Group reported Q3 2026 revenue of $3.71 billion, down 14% year-over-year and missing the consensus estimate of $3.84 billion by 3.31%. EPS of $7.62 beat slightly versus $7.54 a year ago but missed the consensus estimate of $9.38 by 18.76%. Key metrics showed deterioration with a combined ratio of 107.1% versus 101.7% estimated and a total loss ratio of 77% versus 70.9% estimated. The stock has a Zacks Rank #3 (Hold) rating.

Onco360, the nation's leading independent specialty pharmacy, has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy (sunvozertinib), a kinase inhibitor indicated for treating adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations. The partnership expands Onco360's existing relationship with AstraZeneca and leverages its oncology platform to support patient access and care.

Rosen Law Firm is soliciting investors for multiple securities class action lawsuits, including against Doximity, Inc. for allegedly overstating Newsfeed revenue impact and losing market share. The firm is encouraging investors to secure counsel before the November 16, 2026 lead plaintiff deadline. Similar class actions are being pursued against Alphabet Inc. and Ardelyx, Inc.

Rosen Law Firm has filed a securities class action lawsuit against AST SpaceMobile, Inc. on behalf of investors who purchased securities between March 4, 2025 and July 15, 2026. The lawsuit alleges that defendants made false and misleading statements regarding the company's capital requirements, liquidity position, competitive standing in the satellite D2C market, and user adoption rates in the U.S. and Japan. The lead plaintiff deadline is November 13, 2026.

Constellation Energy Corporation (CEG) has attracted investor attention with strong earnings growth expectations of +29.1% for the current fiscal year and +9.3% for the next year. The company has demonstrated solid revenue growth of +39.5% for the current fiscal year and consistently beats consensus estimates. However, it received a Zacks Rank #3 (Hold) rating, suggesting it may perform in line with the broader market in the near term. The stock is valued at par with its peers with a C valuation grade.

ORIC Pharmaceuticals announced promising Phase 1b data for enozertinib in first-line EGFR atypical NSCLC patients, demonstrating 84% confirmed systemic ORR and 70% confirmed intracranial ORR, with an 88% 6-month landmark PFS. The company plans to initiate the Redwood-1 global Phase 3 registrational trial in 1H 2027, enrolling approximately 360 patients.

Eagle Bancorp reported Q3 2026 revenue of $70.87 million, slightly missing consensus estimates by 2.77%, but delivered a significant EPS surprise of $0.79 versus the $0.35 estimate. While the company beat on earnings, it underperformed on net interest income and showed a higher-than-expected efficiency ratio. The stock holds a Zacks Rank #3 (Hold) rating.

HUTCHMED has completed an exclusive development and license agreement with GSK subsidiary, granting GSK worldwide rights (excluding Greater China and Taiwan) to develop and commercialize HMPL-A830, a first-in-class KRAS-EGFR antibody-targeted therapy conjugate. HUTCHMED will receive $110 million upfront and up to $1.185 billion in milestone payments, plus tiered royalties. HUTCHMED remains responsible for global Phase I development.

Pegasystems reported Q3 2026 revenue of $393.36 million, up 3.2% year-over-year but missing the consensus estimate of $429.02 million by 8.31%. EPS of $0.35 fell short of the $0.45 estimate by 22.22%. Key metrics showed mixed results with subscription services growing 10.4% but consulting revenue declining 18.1%. The stock holds a Zacks Rank #3 (Hold) rating.

Constellation Energy has outperformed its industry over three months, driven by long-term contracts with Google and Amazon, a strong 93% nuclear capacity factor, and a diversified clean energy portfolio. However, rising forced outages, higher debt levels relative to peers, and regulatory risks present headwinds. The stock trades at a discount to industry peers but analysts recommend waiting for a more favorable entry point, maintaining a Hold rating.

YD Bio and its affiliate EG BioMed have partnered with digital health provider JoiiUp to integrate an AI-driven cancer risk assessment tool into JoiiUp's JoiiSports app. The assessment, validated using over 1,200 clinical records from Taipei Medical University hospitals, analyzes demographic data and lifestyle factors across ten cancer types without requiring invasive testing. The tool will initially target corporate wellness programs through JoiiUp's network of 400+ companies, with planned expansion to healthcare institutions.

Spyre Therapeutics announced presentations of clinical and preclinical data for its three IBD antibodies (SPY001, SPY002, and SPY003) at UEGW 2026 in Barcelona. The company presented efficacy and safety data for these half-life extended antibodies in moderately to severely active ulcerative colitis, along with preclinical evidence showing additive efficacy of combination approaches. The SKYLINE study is testing these candidates as monotherapies and pairwise combinations, with combination results expected in 2027.

SweetWater Brewing, a craft brewery brand by Tilray Brands, launched a concert sweepstakes giving fans 21+ the chance to win tickets to 2026-2027 AEG concerts at select Georgia venues including Georgia Theatre, The Eastern, Variety Playhouse, and Terminal West. Two winners will be selected with prizes valued at approximately $1,200 each, including concert tickets and travel gift cards. The sweepstakes runs through December 31, 2026.

Rosen Law Firm has filed securities class action lawsuits against FuelCell Energy, Hyliion Holdings, and Tigo Energy, alleging that defendants made false and misleading statements regarding their business operations and financial prospects. Investors who purchased securities during specified class periods are encouraged to secure counsel before upcoming deadlines, with the FuelCell case having a November 10, 2026 lead plaintiff deadline.

Pegasystems (PEGA) is expected to report Q3 2026 earnings of $0.45 per share (up 50% YoY) and revenues of $442.6 million (up 16.1% YoY) on October 20. However, the company has a negative Earnings ESP of -1.68%, indicating recent analyst downgrades, making an earnings beat unlikely. Combined with a Zacks Rank #3 (Hold), PEGA does not appear to be a compelling earnings-beat candidate. The company has missed consensus estimates in the last quarter by 18.60%.

The article discusses a value investing strategy using the PEG ratio (Price/Earnings to Growth) to identify undervalued stocks with strong earnings growth potential. Four stocks meeting specific screening criteria are highlighted: Signet Jewelers showing solid North America sales growth, Micron Technology benefiting from AI-driven demand, Marathon Petroleum with strong expected growth, and International Seaways supported by favorable tanker market fundamentals.

Constellation Energy Corporation (CEG) has been trending on Zacks.com with shares returning +4.7% over the past month, outperforming the S&P 500's +2.4%. The company has a Zacks Rank #2 (Buy) rating based on strong earnings estimate revisions. CEG is expected to report 31.3% year-over-year earnings growth for the current quarter and 29.8% for the fiscal year, with revenue growth of 31.9% projected. The stock is valued at par with peers (C grade) and has consistently beaten consensus estimates.

Eupraxia Pharmaceuticals announced that three abstracts from its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville (October 9-14) and UEG Week 2026 in Barcelona (October 17-20). The presentations will showcase data on improvements in dysphagia and histopathological features persisting over 52 weeks during dose escalation. Phase 2b interim data is expected in December 2026.

Bitdeer Technologies Group (Nasdaq: BTDR) announced expansion of its AI cloud services in Malaysia, securing over 70% off-take commitments for its 21.7MW A201 data center and achieving 100% contracted GPU capacity for its 9.5MW A102 facility. The company is progressing toward its up-to-350MW target capacity at its Cyberjaya campus.

A securities class action lawsuit has been filed against FuelCell Energy, Inc. (FCEL) for allegedly making false and misleading statements regarding manufacturing capacity, production rates, and profitability. The lawsuit covers purchases between June 24, 2026 and September 1, 2026, with a lead plaintiff deadline of November 10, 2026. Investors who purchased FCEL securities during this period may be eligible for compensation.

A securities class action lawsuit has been filed against XTI Aerospace, Inc. for allegedly making materially false and misleading statements during April 15 - August 17, 2026. The lawsuit claims senior executives engaged in undisclosed activities that affected disclosure controls and prevented timely earnings report filings. Investors who purchased securities during this period may be eligible for compensation. The deadline to serve as lead plaintiff is October 27, 2026.

Rosen Law Firm is soliciting investors who purchased Papa John's International (PZZA) stock between August 7, 2025 and August 5, 2026 to join a securities class action lawsuit. The lawsuit alleges that Papa John's made materially false and misleading statements about its transformation efforts, which were taking longer than expected and failed to prevent market share losses, ultimately requiring a shift toward increased promotional efforts.

Rosen Law Firm is notifying investors about securities class action lawsuits, including one against Hyliion Holdings Corp. for allegedly making false statements about its VFG Holdings partnership and commercial pipeline credibility. The firm is seeking a lead plaintiff by October 27, 2026, and encourages affected investors to join the litigation.

Chaince Securities, LLC has been engaged as the exclusive sales agent for Magic Empire Global Limited's (NASDAQ: MEGL) $100 million at-the-market equity offering program. The offering allows MEGL to sell Class A ordinary shares at prevailing market prices, with proceeds intended for working capital and general corporate purposes. This engagement reflects Chaince's expansion of its equity capital markets platform serving Nasdaq-listed issuers.

Cullinan Therapeutics announced the initiation of a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with platinum-based chemotherapy for treating previously untreated EGFR exon 20 insertion NSCLC. The Phase 3 REZILIENT3 trial met its primary endpoint, demonstrating statistically significant improvement in median progression-free survival. The NDA submission is expected to be completed by year-end 2026 under the FDA's Real-Time Oncology Review program.

Lockheed Martin's Rotary and Mission Systems business received a $94.2 million contract modification from the U.S. Navy to support continued development and integration of the AEGIS Combat System for the Royal Canadian Navy. The work, funded through the Foreign Military Sales program, will be completed by December 2027 and includes system engineering, software development, and integration testing.

The article recommends a GARP (Growth at a Reasonable Price) investment strategy that combines value and growth investing principles. Four stocks are highlighted as meeting screening criteria with low PEG ratios, discounted valuations, and strong growth potential: Marathon Petroleum (53.3% expected growth), PBF Energy (55.2% five-year growth), Ultrapar Participações (21.4% growth), and Repsol (21% growth). All four stocks carry Zacks Rank #1 or #2 ratings with Value and Growth scores of A or B.